Xcout IntelNavion Neurosciences Inc. competitors & alternatives
The 12 closest competitors and alternatives to Navion Neurosciences Inc. among biotechnology companies — ranked by similarity to what Navion Neurosciences Inc. actually does, not by market-cap band.
Subscribe to see Navion Neurosciences Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Navion Neurosciences Inc.
Navion Neurosciences, Inc. is a preclinical-stage biotechnology company located in Charlottesville, Virginia, that is developing next-generation, AI-enabled therapies.
Navion Neurosciences Inc. at a glance
Navion Neurosciences Inc. is a biotechnology company headquartered in United States. Its most recent funding round, Seed, raised $10.8M in September 2026. Xcout tracks 8 named people at Navion Neurosciences Inc., including Michael Innes (Chief Business Officer).
Navion Neurosciences Inc. leadership
- Michael InnesChief Business Officer
- Andrew KrouseFounder, President & Chief Executive Officer
- Michelle HigginFounder & Chief Operating Officer
- Manoj PatelFounder & Chief Scientific Officer
- Thomas RichardsonFounder & Director of Chemistry
- Andrew J KrouseExecutive Officer
2 more named people on record for Navion Neurosciences Inc., with roles, board committees and tenure — see the full roster →
Navion Neurosciences Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $10.8M | 6 named | |
| SEC Form D filing | $1.9M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Navion Neurosciences Inc. news
- FundingPrivate placement (Form D)
Top 12 Navion Neurosciences Inc. competitors
Ranked by semantic similarity — how close each company is to Navion Neurosciences Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Nido Biosciences, Inc. is a clinical-stage holding and biotechnology company headquartered in Watertown, Massachusetts. The company focuses on discovering and advancing treatments for debilitating neurological diseases, including the development of targeted drugs.
Biotech
Verge Genomics develops a proprietary AI and machine learning platform utilizing human brain data to transform neuroscience drug discovery and precision neurology. The company provides foundation models and analytical tools to pharmaceutical and biotechnology developers for target discovery, biomarker identification, and clinical trial patient stratification.
Biotech
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, including neuropsychiatric and neurodegenerative disorders. It uses neuroscience, data science, and biomarkers to identify and advance treatments for patients with these conditions.
Biotech
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
Biotech
NanoVation Therapeutics is a platform developer headquartered in Vancouver, British Columbia, that partners with leading pharmaceutical and biotech companies to enable genetic medicines.
Similar biotechnology company
NextPoint Therapeutics is a private biopharmaceutical and technology company based in Cambridge, Massachusetts, focused on expanding novel therapeutic possibilities.
Similar biotechnology company
Prevail Therapeutics Inc. is a biotechnology company headquartered in New York City, New York, focused on developing gene therapies for patients with neurodegenerative diseases.
Similar biotechnology company
Neuron23 is a biotechnology company founded in 2018 that focuses on developing precision therapeutics for genetic diseases. Headquartered in South San Francisco, California, the company relies on a team of scientific experts and entrepreneurs.
Biotech
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Biotech
Elkedonia is a biotechnology company committed to introducing a pioneering, first-in-class antidepressant treatment utilizing precision medicine. Headquartered in Strasbourg, France, the company brings together stakeholders across the European ecosystem to advance innovative therapeutics.
Biotech
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Similar biotechnology company
AIRNA Corporation, Inc. is a biotechnology company headquartered in the United States, focused on delivering precision therapies through its innovative RNA editing platform.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Navion Neurosciences Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Navion Neurosciences Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →